<p>(<b>A</b>) 8226/S, 8226/S-CR, 8226/S-ATOR05 cell lines were treated with the indicated concentrations of ATO for 24 h and apoptosis was assessed by flow cytometry using Annexin V-FITC and PI staining and graphed as percent of control Annexin V positive cells versus drug concentration. (<b>B</b>) 8226/S, 8226/S-CR, 8226/S-ATOR05 cells were treated with 2 µM ATO for 24 h and then collected for intracellular arsenic determination. The data are presented as the mean ± SD of at least 3 independent experiments. Student’s <i>t</i>-test was used to compare differences between 8226/S and 8226-CR and 8226/S-ATOR05 cells, with 95% confidence intervals. *, P<0.05; **, P<0.01; ***, P<0.001.</p
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
Arsenic has long been used as therapeutic agents. Understanding the mechanism of action of arsenic-b...
<div><p>Previously, arsenic trioxide showed impressive regression rates of acute promyelocytic leuke...
<p>(<b>A</b>) 8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the...
<p>(<b>A</b>) 8226/S, 8226/S-CR, 8226/S-ATOR05 control cells were harvested and the intracellular GS...
<p>8226/S, 8226/S-CR, and 8226/S-ATOR05 cells were treated with the indicated concentrations of ATO,...
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
<p>(A) MDA-MB-468, MCF-7, SkBr3, and T47D cell lines were exposed to vehicle control (Vh; 5.3 x 10<...
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
<p>Scatter plot of the intracellular concentration of arsenic levels in newly diagnosed patients (N ...
<p>8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the absence of...
<p>Untreated cells (top panel) and cells treated with ATO (bottom panel) were then analyzed by stain...
<p>Viability of HSC5 cells treated with 0, 1.0, 3.0 and 5.0 µM of arsenic was evaluated by crystal v...
Small cell lung cancer (SCLC) is characterized by prompt response to chemotherapy and radiotherapy b...
<p>(a) MDCK cells were plated in 24 well plates (2.05 cm<sup>2</sup> surface) and then exposed to pr...
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
Arsenic has long been used as therapeutic agents. Understanding the mechanism of action of arsenic-b...
<div><p>Previously, arsenic trioxide showed impressive regression rates of acute promyelocytic leuke...
<p>(<b>A</b>) 8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the...
<p>(<b>A</b>) 8226/S, 8226/S-CR, 8226/S-ATOR05 control cells were harvested and the intracellular GS...
<p>8226/S, 8226/S-CR, and 8226/S-ATOR05 cells were treated with the indicated concentrations of ATO,...
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
<p>(A) MDA-MB-468, MCF-7, SkBr3, and T47D cell lines were exposed to vehicle control (Vh; 5.3 x 10<...
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
<p>Scatter plot of the intracellular concentration of arsenic levels in newly diagnosed patients (N ...
<p>8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the absence of...
<p>Untreated cells (top panel) and cells treated with ATO (bottom panel) were then analyzed by stain...
<p>Viability of HSC5 cells treated with 0, 1.0, 3.0 and 5.0 µM of arsenic was evaluated by crystal v...
Small cell lung cancer (SCLC) is characterized by prompt response to chemotherapy and radiotherapy b...
<p>(a) MDCK cells were plated in 24 well plates (2.05 cm<sup>2</sup> surface) and then exposed to pr...
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success....
Arsenic has long been used as therapeutic agents. Understanding the mechanism of action of arsenic-b...
<div><p>Previously, arsenic trioxide showed impressive regression rates of acute promyelocytic leuke...